Breaking News Instant updates and real-time market news.

GKOS

Glaukos

$69.84

25.05 (55.93%)

10:00
08/29/18
08/29
10:00
08/29/18
10:00

Glaukos rises 55.4%

Glaukos is up 55.4%, or $24.80 to $69.60.

  • 05

    Sep

GKOS Glaukos
$69.84

25.05 (55.93%)

08/24/18
WELS
08/24/18
NO CHANGE
Target $50
WELS
Outperform
Ivantis counterclaim against Glaukos looks weak, says Wells Fargo
Following a review by his firm's patent consultant, Wells Fargo analyst Larry Biegelsen says Ivantis' counterclaim, alleging that Glaukos' new iStent inject product will infringe three Ivantis patents, appears weak. The Ivantis patents very specifically add a detail about the placement of the shunt, which reads as "too straightforward" or "obvious," the patent consultant told the analyst. As such, he believes the patents will ultimately be found invalid. Biegelsen keeps an Outperform rating on Glaukos with a $50 price target.
08/29/18
WBLR
08/29/18
NO CHANGE
WBLR
Outperform
CyPass market removal a 'clear positive' for Glaukos, says William Blair
William Blair analyst Brian Weinstein believes Alcon's voluntary global market withdrawal of its CyPass Micro-Stent for surgical glaucoma is a "clear positive for near-term numbers" at Glaukos (GKOS). If Glaukos' iStent takes all of the CyPass market share while it is off the market, the company could add as much as $50M in the U.S. alone to its 2019 total revenue of around $186M, Weinstein tells investors in a research note, while admitting this is a bullish stance. The analyst thinks the news this morning from Alcon should be viewed as a positive for Glaukos, as a major part of the short thesis was on competition in the core iStent market, mainly from Alcon. He keeps an Outperform rating on Glaukos shares.
08/29/18
PIPR
08/29/18
NO CHANGE
Target $55
PIPR
Overweight
Piper sees CyPass withdrawal as 'major boon' for Glaukos, ups target to $55
Piper Jaffray analyst Matt O'Brien views Alcon's immediate withdrawal of its CyPass stent for the treatment of glaucoma on safety concerns from a recently completed clinical study as a "major boon" for Glaukos (GKOS). The analyst suspects it will be several quarters before CyPass comes back to the market, with with a much narrower indication. This is a "major positive" for Glaukos as most of the clinicians using CyPass had been or are still using iStent from Glaukos, O'Brien tells investors in a research note. He anticipates many clinicians will quickly shift their volumes back to iSten, yielding "significant incremental revenues." Based on this morning's news, the analyst raised his price target for Glaukos shares to $55 from $46. He encourages investors to start or build positions in the name.
08/29/18
SPHN
08/29/18
NO CHANGE
Target $57
SPHN
Overweight
Glaukos price target raised to $57 at Stephens after Novartis withdraws CyPass
Stephens analyst Chris Cooley raised his price target on Glaukos (GKOS) shares to $57 from $50 after Novartis' (NVS) Alcon unit withdrew the CyPass micro-stent from the market due to safety concerns. He estimates $40M-$50M in annual sales are now "in play" and see Glaukos as the most likely beneficiary, Cooley tells investors. He maintains an Overweight rating on Glaukos shares, which are up $17.35, or 39%, to $62.15 in pre-market trading.

TODAY'S FREE FLY STORIES

02:40
12/13/18
12/13
02:40
12/13/18
02:40
General news
FX Update: A risk-on theme has been coursing through forex markets »

FX Update: A risk-on…

01:45
12/13/18
12/13
01:45
12/13/18
01:45
General news
Asian Market Wrap: »

Asian Market Wrap:…

BHVN

Biohaven Pharmaceutical

$37.72

1.02 (2.78%)

20:51
12/12/18
12/12
20:51
12/12/18
20:51
Syndicate
Biohaven Pharmaceutical 3.3M share Secondary priced at $37.25 per share »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

FIVE

Five Below

$101.38

1.86 (1.87%)

20:48
12/12/18
12/12
20:48
12/12/18
20:48
Upgrade
Five Below rating change at Goldman Sachs »

Five Below upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRNS

Marinus Pharmaceuticals

$4.21

-0.89 (-17.45%)

20:28
12/12/18
12/12
20:28
12/12/18
20:28
Syndicate
Marinus Pharmaceuticals 12M share Secondary priced at $3.75 per share »

Jefferies and Leerink are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

UNM

Unum Group

$30.27

-0.04 (-0.13%)

20:25
12/12/18
12/12
20:25
12/12/18
20:25
Hot Stocks
Unum Group sees FY19 adjusted EPS growth of 4%-7% »

Sees FY19 tax rate of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CIEN

Ciena

$32.14

0.535 (1.69%)

20:25
12/12/18
12/12
20:25
12/12/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

TDC

Teradata

$38.02

0.65 (1.74%)

20:18
12/12/18
12/12
20:18
12/12/18
20:18
Hot Stocks
Teradata targets 2021 recurring revenue growth of 14% »

Also sees 2021 gross…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 19

    Dec

  • 20

    Dec

HESM

Hess Midstream Partners

$19.43

0.38 (1.99%)

19:09
12/12/18
12/12
19:09
12/12/18
19:09
Hot Stocks
Hess Midstream Partners sees FY19 adjusted EBITDA $550M-$575M »

Sees FY19: net income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOCA

Tocagen

$11.22

-1.63 (-12.68%)

19:05
12/12/18
12/12
19:05
12/12/18
19:05
Syndicate
Tocagen 3M share Secondary priced at $10.00 per share »

Citi and Leerink are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

ALL

Allstate

$82.37

-0.12 (-0.15%)

19:03
12/12/18
12/12
19:03
12/12/18
19:03
Hot Stocks
Allstate announces estimated November catastrophe losses of $685M »

Allstate announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$76.04

-0.64 (-0.83%)

19:01
12/12/18
12/12
19:01
12/12/18
19:01
Hot Stocks
Exxon makes final investment decision to develop West Barracouta gas project »

ExxonMobil said that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDSN

Nordson

$111.83

1.09 (0.98%)

, JCS

Communications Systems

$2.42

0.2 (9.01%)

19:00
12/12/18
12/12
19:00
12/12/18
19:00
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

NDSN

Nordson

$111.83

1.09 (0.98%)

JCS

Communications Systems

$2.42

0.2 (9.01%)

BW

Babcock & Wilcox

$0.77

0.0569 (7.94%)

FIVE

Five Below

$101.38

1.86 (1.87%)

BABA

Alibaba

$151.49

-0.34 (-0.22%)

TLRD

Tailored Brands

$20.16

0.32 (1.61%)

LLNW

Limelight Networks

$3.20

0.025 (0.79%)

OXM

Oxford Industries

$74.88

0.895 (1.21%)

AGTC

Applied Genetic

$6.61

0.54 (8.90%)

VBIV

VBI Vaccines

$1.66

0.08 (5.06%)

HASI

Hannon Armstrong

$23.10

-0.16 (-0.69%)

BVN

Buenaventura

$15.25

0.22 (1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 13

    Dec

  • 04

    Mar

  • 12

    Mar

  • 13

    Dec

  • 13

    Dec

OXM

Oxford Industries

$74.88

0.895 (1.21%)

18:58
12/12/18
12/12
18:58
12/12/18
18:58
Earnings
Oxford Industries cuts FY18 EPS view to $4.20-$4.35 from $4.45-$4.65 »

Cuts FY18 revenue view to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

OXM

Oxford Industries

$74.88

0.895 (1.21%)

18:56
12/12/18
12/12
18:56
12/12/18
18:56
Earnings
Oxford Industries sees Q4 EPS 96c-$1.11 vs. 93c last year »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

OXM

Oxford Industries

$74.88

0.895 (1.21%)

18:55
12/12/18
12/12
18:55
12/12/18
18:55
Earnings
Oxford Industries reports Q3 adjusted EPS 14c vs. 17c last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

NEXT

NextDecade

$4.74

0.04 (0.85%)

18:30
12/12/18
12/12
18:30
12/12/18
18:30
Hot Stocks
NextDecade's Rio Grande LNG project approved by TCEQ »

NextDecade Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$89.63

1.49 (1.69%)

18:15
12/12/18
12/12
18:15
12/12/18
18:15
Periodicals
United CEO seeks to boost flight network by 4%-6% next year, Reuters says »

United Airlines CEO Oscar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

AKAO

Achaogen

$1.80

0.06 (3.45%)

17:58
12/12/18
12/12
17:58
12/12/18
17:58
Hot Stocks
Breaking Hot Stocks news story on Achaogen »

Robert Duggan raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLR

Fluor

$34.11

0.29 (0.86%)

17:56
12/12/18
12/12
17:56
12/12/18
17:56
Hot Stocks
Fluor announces participation in $2.1B rail project in Chicago »

Fluor announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIVE

Five Below

$101.38

1.86 (1.87%)

17:55
12/12/18
12/12
17:55
12/12/18
17:55
Upgrade
Five Below rating change at Goldman Sachs »

Five Below upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTC

Bitcoin

$0.00

(0.00%)

, BITCOIN

Bitcoin

$0.00

(0.00%)

17:49
12/12/18
12/12
17:49
12/12/18
17:49
Hot Stocks
SEC says former execs behind allegedly fraudulent ICO settle scam charges »

Two former executives…

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PK

Park Hotels & Resorts

$29.28

0.08 (0.27%)

17:44
12/12/18
12/12
17:44
12/12/18
17:44
Hot Stocks
Park Hotels & Resorts announces Q4 dividend of $1.00 per share »

Park Hotels & Resorts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PK

Park Hotels & Resorts

$29.28

0.08 (0.27%)

17:44
12/12/18
12/12
17:44
12/12/18
17:44
Hot Stocks
Park Hotels & Resorts announces Q4 dividend of $1.00 per share »

Park Hotels & Resorts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNP

CenterPoint Energy

$28.90

0.12 (0.42%)

17:37
12/12/18
12/12
17:37
12/12/18
17:37
Hot Stocks
CenterPoint Energy raises dividend 4% to 28.75c per share »

The company's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.